[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Dynasthetics LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":105},{"warningLetters":4,"total":104},[5,31,53,73,85],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},593,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-09-16T13:20:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fexpert-aesthetics-715796-09092025\">Expert Aesthetics\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brenda Burr RN, MSN\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Expert Aesthetics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1551 US Hwy 287 N. Frontage Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mansfield\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76063\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:expert.aesthetics@gmail.com\"> expert.aesthetics@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Ms. Burr:&nbsp;\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Ferasingage.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.\u003Ca id=\"footnoteref1_mu0ht8g\" href=\"#footnote1_mu0ht8g\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].&nbsp;\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.&nbsp;\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide and tirzepatide products appear on your website:&nbsp;\u003C\u002Fp>\u003Cp>• “At home weight loss with the popular Ozempic generic Semaglutide.”&nbsp;\u003C\u002Fp>\u003Cp>• “At home weight loss with the popular Mounjaro generic Tirzepatide.”&nbsp;\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].&nbsp;\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_uz61uta\" href=\"#footnote2_uz61uta\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>&nbsp;&nbsp;\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].&nbsp;\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.&nbsp;\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.&nbsp;\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.&nbsp;\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.&nbsp;\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>Sincerely,&nbsp;\u003C\u002Fp>\u003Cp>\u002Fs\u002F&nbsp;\u003C\u002Fp>\u003Cp>George Tidmarsh, M.D., Ph.D.&nbsp;\u003C\u002Fp>\u003Cp>Director&nbsp;\u003C\u002Fp>\u003Cp>Center for Drug Evaluation and Research&nbsp;\u003C\u002Fp>\u003Cp>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_mu0ht8g\">\u003Ca href=\"#footnoteref1_mu0ht8g\">1\u003C\u002Fa>The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_uz61uta\">\u003Ca href=\"#footnoteref2_uz61uta\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nBrenda Burr RN, MSN\n\nRecipient Title\n\nOwner\n\nExpert Aesthetics\n\n1551 US Hwy 287 N. Frontage Rd.\n\nMansfield, TX 76063\n\nUnited States\n\nexpert.aesthetics@gmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nMs. Burr:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Ferasingage.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.1 As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n• “At home weight loss with the popular Ozempic generic Semaglutide.”\n• “At home weight loss with the popular Mounjaro generic Tirzepatide.”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\n\nSincerely,\n\u002Fs\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Expert Aesthetics","expert-aesthetics-715796-09092025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fexpert-aesthetics-715796-09092025","2026-10-26T08:08:38.410623+00:00","Warning Letter","Issued","2025-09-16","715796","Drugs","Brenda Burr RN, MSN","2026-08-19T16:21:11.078+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2025-09-09",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},2946,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2021-12-28T14:20:00Z\">12\u002F28\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-24T05:00:00Z\">11\u002F24\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdsaart-llc-dba-alpha-aesthetics-618157-11242021\">DSAART, LLC. dba Alpha Aesthetics\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FManufacture\u002FPacking\u002FStorage\u002FInstallation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Douglas Steinbrech\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DSAART, LLC. dba Alpha Aesthetics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2950 Arrowhead Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Carson City\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89706\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dss@drsteinbrech.com\"> dss@drsteinbrech.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS 618157\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 24, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Steinbrech:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your medical device operations at 2950 Arrowhead Dr., Carson City, NV 89706 from July 19, 2021 through August 5, 2021. During the inspection, an FDA Investigator determined that your firm is a manufacturer of silicone facial and body contouring implants. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that your silicone implant devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your firm’s responses dated August 27, 2021 and September 24, 2021 concerning our Investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on August 5, 2021. We acknowledge your firm’s response states you have hired a 3rd party consultant to assist with your corrective actions. Additionally, your response includes corrective and preventive action (CAPA) records opened for each observation listed on the FDA 483, Inspectional Observations. We address each response below.\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example,\u003C\u002Fp>\n\n\u003Cp>a. Your firm uses a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> designated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to sterilize your silicone implant devices. Your firm has not qualified this \u003Cstrong>(b)(4)\u003C\u002Fstrong> can deliver your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process with a high degree of assurance.\u003C\u002Fp>\n\n\u003Cp>b. Your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> to cure your silicone implants as part of your manufacturing process. Your firm has not validated this curing process.\u003C\u002Fp>\n\n\u003Cp>c. Your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> to seal the packaging for your sterile silicone implants. Your firm has not validated the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses and determined they are inadequate. Your firm’s response dated September 24, 2021 acknowledges your firm has not validated the referenced processes and states your firm is working to identify methods of validation. However, there is insufficient information for us to evaluate the adequacy of these corrective actions as no validation plans have been provided. Further, your response does not address what containment or interim actions your firm intends to take to ensure compliance of products until your firm can complete the required validations.\u003C\u002Fp>\n\n\u003Cp>In regard to your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your firm provided “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, SOP QA032, Rev. A dated September 8, 2021. However, this procedure does not meet the requirements of 21 CFR 820.75. The provided procedure appears to be an acceptance testing procedure. Your firm’s process validation activities should provide objective evidence your process can consistently produce product or results meeting predetermined acceptance criteria. Our website,&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftraining-and-continuing-education\u002Fcdrh-learn\">https:\u002F\u002Fwww.fda.gov\u002Ftraining-and-continuing-education\u002Fcdrh-learn\u003C\u002Fa> provides training and references which you may find useful in complying with the process validation and other quality system requirements.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm has not adequately documented the nature and details of complaints or the dates and results of investigations conducted as required by 21 CFR 820.198(e). Further, your firm has not documented justifications for not conducting investigations for complaints alleging your devices failed to meet specifications as required by 21 CFR 820.198(b). For example,\u003C\u002Fp>\n\n\u003Cp>a. Your firm received complaint 01-014-01 dated January 14, 2021 alleging the physician had trouble implanting the gluteal implant. The complaint record states the device was returned and tested; however, you do not have records of this testing and the results.\u003C\u002Fp>\n\n\u003Cp>b. Your firm received complaint 19-295-01 dated October 22, 2019 identifying the gluteal implant was removed due to the patient suffering from chronic inflammation. The complaint record states the root cause could not be determined; however, it does not document what actions were taken to reach this conclusion.\u003C\u002Fp>\n\n\u003Cp>c. Your firm received complaint 19-324-01 dated November 20, 2019 reporting the gluteal implant was explanted after having broken into three pieces. The complaint record states the doctor refused to provide additional information to complete the complaint record; however, your firm did receive a serial number for the device and did not document any investigation into the event.\u003C\u002Fp>\n\n\u003Cp>d. Your firm received complaint 20-003-01 dated January 3, 2020 which reported the gluteal implant was removed due to swelling. However, the investigation section of the complaint form is blank.\u003C\u002Fp>\n\n\u003Cp>e. Your firm received complaint 20-008-01 dated January 8, 2020 which reported a pectoral implant was removed due to seroma at the implant site. However, the investigation section of the complaint form is blank.\u003C\u002Fp>\n\n\u003Cp>f. Your firm received complaint 20-196-01 dated July 14, 2020 which reported the gluteal implant ruptured and was explanted. The complaint record identifies the patient status after treatment but does not include records the complaint was investigated.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and are unable to determine its adequacy at this time. Your firm’s response includes revisions to your complaint procedure to better define requirements for investigations. Additionally, your response includes documentation showing your firm reevaluated the referenced complaints using your revised complaint form. However, this redocumentation of your complaints does not address the investigation deficiencies identified; the same information originally documented is just redocumented on the new form. Further, your response states your firm will conduct a retrospective review of all complaints received previously, however, this activity has not been completed. It is unclear if your revised complaint procedures effectively ensure your firm will conduct and document thorough complaint investigations moving forward.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, on June 15, 2020, your firm initiated a Corrective and Preventive Action Questionnaire in response to identifying your \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees instead of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>degrees as set. Your firm’s questionnaire does not include records indicating if this event occurred in a manner that could affect product. Your record documents your firm conducted a \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, your firm did not assess the impact or cause of the process nonconformance.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses and determined they are inadequate. Your firm’s response states you have made changes to your CAPA processes including revision to your Corrective and Preventive Action Questionnaire to include changes to scope and risk assessment. However, your corresponding CAPA procedure does not include any revisions to detail how to complete these activities. Additionally, your response does not address any specific review of the CAPA Questionnaire specifically referenced in the observation.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain adequate procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, your firm’s Non-Conforming Products and Corrective and Preventive Action (Document Number QA012 Rev. B, Date Effective January 9, 2003) states when nonconforming products are identified, they should be reported to Quality Assurance for disposition. However, the procedure does not describe how this disposition will be documented. Additionally, your firm identified nonconforming products in lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> (gluteal implant) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (pectoral implants) and there is no record of the evaluation and disposition of these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses and determined they are inadequate. Your firm’s response identifies some modifications to your Non-Conforming Products and Corrective and Preventive Action (Document Number QA012 Rev. B, Date Effective January 9, 2003) involving product rework. However, these revised procedures continue to fail to address how the disposition and review of products will be documented. Additionally, your response does not include an evaluation of the two specific examples of nonconforming products listed on the FDA 483.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain adequate design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g). Specifically, your firm’s Design Control procedure, Document Number QA004 Rev. A, Date effective May 6, 2002 requires design validation to be conducted but does not provide procedures to be followed. Additionally, your firm applies a five-year shelf life to your silicone implants. However, your firm did not adequately validate this shelf life. Your firm provided a memo dated March 17, 2007 identifying products were tested; however, it does not include records identifying the justification for the sample size, test methods used, equipment used, or how many samples were tested after accelerated aging.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses and determined they are inadequate. Your firm’s responses state you have revaluated your validation of the 5 year shelf-life and provided the supporting records. However, these records of your validation do not address the deficiencies with the validation identified during the inspection and noted above. Additionally, your provided records only address product sterility testing and do not address if your products continue to meet all appropriate quality specifications over this timeframe.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s silicone implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\n\n\u003Cp>For example, the information included for Complaint #19-295-01, #20-003-01 and #20-008-01, reasonably suggests patients sustained an injury or illness (e.g., swelling, chronic inflammation and seromas) after the procedure was conducted using your firm’s Gluteal or Pectoralis Implants. The patient referenced for Complaint #19-295-01 received antibiotics and all patients referenced for each complaint underwent a procedure to explant the device. We believe that device explantation from a patient after sustaining an injury post device implant, represents an event in which your firm’s device may have caused or contributed to patient injury that necessitated medical intervention, such as device explant, to preclude permanent impairment of a body function or permanent damage to a body structure. There is no information included for the complaints that rules out that the device may not have caused or contributed to the referenced serious injuries. Your firm became aware of Complaint 19-295-01 on October 22, 2019; Complaint 20-003-01 on January 3, 2020 and Complaint 20-008-01 on January 8, 2020. Per our records, no serious injury MDR has been received by the FDA for each of the above referenced complaints.\u003Cbr>\n\u003Cbr>\nYour firm’s response dated August 27, 2021, is not adequate. The response notes that your firm plans to review its compliance with the 803 requirements, \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>employees and submit a report for each MDR reportable event by September 15, 2021. However, your firm did not provide documentation or evidence of the systemic corrective actions, including a retrospective review of its adverse events. In addition, the response did not include evidence that your firm submitted a serious injury report for each of the referenced Complaints.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response dated September 24, 2021, is not adequate. The response notes that your firm continues to \u003Cstrong>(b)(4)\u003C\u002Fstrong> its MDR reportability process and is in the process of completing enrollment in the electronic MDR submission. However, your firm did not provide documentation or evidence of the systemic corrective actions, including a retrospective review of its adverse events. In addition, the response did not include evidence that your firm submitted a serious injury report for each of the referenced Complaints.\u003C\u002Fp>\n\n\u003Cp>2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information included for Complaints #19-324-01 and #20-196-01 reasonably suggests that your firm’s device fractured. These fractures were noted after device explant. Per the Preamble, in the \u003Cem>Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (Dec. 11, 1995)\u003C\u002Fem>, Comment 12, the malfunction of a long-term implantable device is reportable. There is no information included in your firm’s complaints that rules out that the malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. As such, the referenced complaints meet the definition of an MDR Reportable Event, as defined in 21 CFR 803.3. Your firm became aware of Complaint #19-324-01 on November 20, 2019 and Complaint #20-196-01 on July 12, 2020. Per our records, no malfunction MDR has been received by the FDA for each of the referenced Complaints.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately develop, maintain and implement written MDR procedures to establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). For example, your firm’s MDR procedure titled ”Medical Device Vigilance System and Medical Device Reporting”, SOP QA013, Revision B, dated 5\u002F6\u002F20, does not include a process for submitting MDRs electronically in accordance with 21 CFR 803.20(a)(3).\u003Cbr>\n\u003Cbr>\nFor information regarding the electronic submission of MDRs, refer to the FDA guidance document\u003Cstrong> Questions and Answers about eMDR - Electronic Medical Device Reporting\u003C\u002Fstrong>. In addition, see the guidance document \u003Cstrong>eMDR – Electronic Medical Device Reporting\u003C\u002Fstrong> for details on how to set up an account for submitting these reports.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at ORADevices3 FirmResponse@fda.hhs.gov. Please identify your response with FEI 3003897287.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact Compliance Officer Jeff R. Wooley at 214-253-5251, or via e-mail at jeffrey.wooley@fda.hhs.gov.\u003Cbr>\n\u003Cbr>\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological\u003Cbr>\nHealth, Division 3\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Binita S. Ashar, MD, MBA, FACS\u003Cbr>\nDirector\u003Cbr>\nOHT 4: Office of Office of Surgery and\u003Cbr>\nInfection Control Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDouglas Steinbrech\n\nRecipient Title\n\nOwner and President\n\nDSAART, LLC. dba Alpha Aesthetics\n\n2950 Arrowhead Dr.\n\nCarson City, NV 89706\n\nUnited States\n\ndss@drsteinbrech.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS 618157\n\nNovember 24, 2021\n\nDear Mr. Steinbrech:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your medical device operations at 2950 Arrowhead Dr., Carson City, NV 89706 from July 19, 2021 through August 5, 2021. During the inspection, an FDA Investigator determined that your firm is a manufacturer of silicone facial and body contouring implants. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that your silicone implant devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your firm’s responses dated August 27, 2021 and September 24, 2021 concerning our Investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on August 5, 2021. We acknowledge your firm’s response states you have hired a 3rd party consultant to assist with your corrective actions. Additionally, your response includes corrective and preventive action (CAPA) records opened for each observation listed on the FDA 483, Inspectional Observations. We address each response below.\n\n1. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example,\n\na. Your firm uses a (b)(4), (b)(4) designated (b)(4), to sterilize your silicone implant devices. Your firm has not qualified this (b)(4) can deliver your (b)(4) process with a high degree of assurance.\n\nb. Your firm uses (b)(4) to cure your silicone implants as part of your manufacturing process. Your firm has not validated this curing process.\n\nc. Your firm uses (b)(4) to seal the packaging for your sterile silicone implants. Your firm has not validated the (b)(4) process.\n\nWe have reviewed your responses and determined they are inadequate. Your firm’s response dated September 24, 2021 acknowledges your firm has not validated the referenced processes and states your firm is working to identify methods of validation. However, there is insufficient information for us to evaluate the adequacy of these corrective actions as no validation plans have been provided. Further, your response does not address what containment or interim actions your firm intends to take to ensure compliance of products until your firm can complete the required validations.\n\nIn regard to your (b)(4), your firm provided “(b)(4)”, SOP QA032, Rev. A dated September 8, 2021. However, this procedure does not meet the requirements of 21 CFR 820.75. The provided procedure appears to be an acceptance testing procedure. Your firm’s process validation activities should provide objective evidence your process can consistently produce product or results meeting predetermined acceptance criteria. Our website, https:\u002F\u002Fwww.fda.gov\u002Ftraining-and-continuing-education\u002Fcdrh-learn provides training and references which you may find useful in complying with the process validation and other quality system requirements.\n\n2. Failure to adequately maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm has not adequately documented the nature and details of complaints or the dates and results of investigations conducted as required by 21 CFR 820.198(e). Further, your firm has not documented justifications for not conducting investigations for complaints alleging your devices failed to meet specifications as required by 21 CFR 820.198(b). For example,\n\na. Your firm received complaint 01-014-01 dated January 14, 2021 alleging the physician had trouble implanting the gluteal implant. The complaint record states the device was returned and tested; however, you do not have records of this testing and the results.\n\nb. Your firm received complaint 19-295-01 dated October 22, 2019 identifying the gluteal implant was removed due to the patient suffering from chronic inflammation. The complaint record states the root cause could not be determined; however, it does not document what actions were taken to reach this conclusion.\n\nc. Your firm received complaint 19-324-01 dated November 20, 2019 reporting the gluteal implant was explanted after having broken into three pieces. The complaint record states the doctor refused to provide additional information to complete the complaint record; however, your firm did receive a serial number for the device and did not document any investigation into the event.\n\nd. Your firm received complaint 20-003-01 dated January 3, 2020 which reported the gluteal implant was removed due to swelling. However, the investigation section of the complaint form is blank.\n\ne. Your firm received complaint 20-008-01 dated January 8, 2020 which reported a pectoral implant was removed due to seroma at the implant site. However, the investigation section of the complaint form is blank.\n\nf. Your firm received complaint 20-196-01 dated July 14, 2020 which reported the gluteal implant ruptured and was explanted. The complaint record identifies the patient status after treatment but does not include records the complaint was investigated.\n\nWe have reviewed your firm’s response and are unable to determine its adequacy at this time. Your firm’s response includes revisions to your complaint procedure to better define requirements for investigations. Additionally, your response includes documentation showing your firm reevaluated the referenced complaints using your revised complaint form. However, this redocumentation of your complaints does not address the investigation deficiencies identified; the same information originally documented is just redocumented on the new form. Further, your response states your firm will conduct a retrospective review of all complaints received previously, however, this activity has not been completed. It is unclear if your revised complaint procedures effectively ensure your firm will conduct and document thorough complaint investigations moving forward.\n\n3. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, on June 15, 2020, your firm initiated a Corrective and Preventive Action Questionnaire in response to identifying your (b)(4) was (b)(4) degrees instead of (b)(4) degrees as set. Your firm’s questionnaire does not include records indicating if this event occurred in a manner that could affect product. Your record documents your firm conducted a (b)(4); however, your firm did not assess the impact or cause of the process nonconformance.\n\nWe have reviewed your responses and determined they are inadequate. Your firm’s response states you have made changes to your CAPA processes including revision to your Corrective and Preventive Action Questionnaire to include changes to scope and risk assessment. However, your corresponding CAPA procedure does not include any revisions to detail how to complete these activities. Additionally, your response does not address any specific review of the CAPA Questionnaire specifically referenced in the observation.\n\n4. Failure to establish and maintain adequate procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, your firm’s Non-Conforming Products and Corrective and Preventive Action (Document Number QA012 Rev. B, Date Effective January 9, 2003) states when nonconforming products are identified, they should be reported to Quality Assurance for disposition. However, the procedure does not describe how this disposition will be documented. Additionally, your firm identified nonconforming products in lots (b)(4) (gluteal implant) and (b)(4) (pectoral implants) and there is no record of the evaluation and disposition of these nonconforming products.\n\nWe have reviewed your responses and determined they are inadequate. Your firm’s response identifies some modifications to your Non-Conforming Products and Corrective and Preventive Action (Document Number QA012 Rev. B, Date Effective January 9, 2003) involving product rework. However, these revised procedures continue to fail to address how the disposition and review of products will be documented. Additionally, your response does not include an evaluation of the two specific examples of nonconforming products listed on the FDA 483.\n\n5. Failure to establish and maintain adequate design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g). Specifically, your firm’s Design Control procedure, Document Number QA004 Rev. A, Date effective May 6, 2002 requires design validation to be conducted but does not provide procedures to be followed. Additionally, your firm applies a five-year shelf life to your silicone implants. However, your firm did not adequately validate this shelf life. Your firm provided a memo dated March 17, 2007 identifying products were tested; however, it does not include records identifying the justification for the sample size, test methods used, equipment used, or how many samples were tested after accelerated aging.\n\nWe have reviewed your responses and determined they are inadequate. Your firm’s responses state you have revaluated your validation of the 5 year shelf-life and provided the supporting records. However, these records of your validation do not address the deficiencies with the validation identified during the inspection and noted above. Additionally, your provided records only address product sterility testing and do not address if your products continue to meet all appropriate quality specifications over this timeframe.\n\nOur inspection also revealed that your firm’s silicone implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\n\nFor example, the information included for Complaint #19-295-01, #20-003-01 and #20-008-01, reasonably suggests patients sustained an injury or illness (e.g., swelling, chronic inflammation and seromas) after the procedure was conducted using your firm’s Gluteal or Pectoralis Implants. The patient referenced for Complaint #19-295-01 received antibiotics and all patients referenced for each complaint underwent a procedure to explant the device. We believe that device explantation from a patient after sustaining an injury post device implant, represents an event in which your firm’s device may have caused or contributed to patient injury that necessitated medical intervention, such as device explant, to preclude permanent impairment of a body function or permanent damage to a body structure. There is no information included for the complaints that rules out that the device may not have caused or contributed to the referenced serious injuries. Your firm became aware of Complaint 19-295-01 on October 22, 2019; Complaint 20-003-01 on January 3, 2020 and Complaint 20-008-01 on January 8, 2020. Per our records, no serious injury MDR has been received by the FDA for each of the above referenced complaints.\n\nYour firm’s response dated August 27, 2021, is not adequate. The response notes that your firm plans to review its compliance with the 803 requirements, (b)(4) employees and submit a report for each MDR reportable event by September 15, 2021. However, your firm did not provide documentation or evidence of the systemic corrective actions, including a retrospective review of its adverse events. In addition, the response did not include evidence that your firm submitted a serious injury report for each of the referenced Complaints.\n\nYour firm’s response dated September 24, 2021, is not adequate. The response notes that your firm continues to (b)(4) its MDR reportability process and is in the process of completing enrollment in the electronic MDR submission. However, your firm did not provide documentation or evidence of the systemic corrective actions, including a retrospective review of its adverse events. In addition, the response did not include evidence that your firm submitted a serious injury report for each of the referenced Complaints.\n\n2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, the information included for Complaints #19-324-01 and #20-196-01 reasonably suggests that your firm’s device fractured. These fractures were noted after device explant. Per the Preamble, in the Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (Dec. 11, 1995), Comment 12, the malfunction of a long-term implantable device is reportable. There is no information included in your firm’s complaints that rules out that the malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. As such, the referenced complaints meet the definition of an MDR Reportable Event, as defined in 21 CFR 803.3. Your firm became aware of Complaint #19-324-01 on November 20, 2019 and Complaint #20-196-01 on July 12, 2020. Per our records, no malfunction MDR has been received by the FDA for each of the referenced Complaints.\n\n3. Failure to adequately develop, maintain and implement written MDR procedures to establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). For example, your firm’s MDR procedure titled ”Medical Device Vigilance System and Medical Device Reporting”, SOP QA013, Revision B, dated 5\u002F6\u002F20, does not include a process for submitting MDRs electronically in accordance with 21 CFR 803.20(a)(3).\n\nFor information regarding the electronic submission of MDRs, refer to the FDA guidance document Questions and Answers about eMDR - Electronic Medical Device Reporting. In addition, see the guidance document eMDR – Electronic Medical Device Reporting for details on how to set up an account for submitting these reports.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nYour response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at ORADevices3 FirmResponse@fda.hhs.gov. Please identify your response with FEI 3003897287.\n\nIf you have any questions about the contents of this letter, please contact Compliance Officer Jeff R. Wooley at 214-253-5251, or via e-mail at jeffrey.wooley@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological\n\nHealth, Division 3\n\n\u002FS\u002F\n\nBinita S. Ashar, MD, MBA, FACS\n\nDirector\n\nOHT 4: Office of Office of Surgery and\n\nInfection Control Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","DSAART, LLC. dba Alpha Aesthetics","dsaart-llc-dba-alpha-aesthetics-618157-11242021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdsaart-llc-dba-alpha-aesthetics-618157-11242021","2026-10-26T08:08:28.012578+00:00","2021-12-28","618157","Medical Devices","Douglas Steinbrech","2026-08-20T02:17:52.628+00:00","VIA Electronic Mail","2021-11-24",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},286,[56,57,58,11,59,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-20T05:00:00Z\">02\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspen-aesthetics-dba-fifty-410-721481-02202026\">Aspen Aesthetics dba Fifty 410\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Aspen Aesthetics dba Fifty 410\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1630 W Prosper Trail, #620\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Prosper\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75078\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:help@fifty410.com\"> help@fifty410.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>Fifty 410:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.fifty410.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide and tirzepatide products displayed on your website identify “Fifty 410” on the pictured label, suggesting Fifty 410 is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that Fifty 410 is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>Additionally, the following claim concerning compounded semaglutide and tirzepatide products appears on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“clinically proven ingredients”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claim implies that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nAspen Aesthetics dba Fifty 410\n\n1630 W Prosper Trail, #620\n\nProsper, TX 75078\n\nUnited States\n\nhelp@fifty410.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nFifty 410:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.fifty410.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide and tirzepatide products displayed on your website identify “Fifty 410” on the pictured label, suggesting Fifty 410 is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that Fifty 410 is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nAdditionally, the following claim concerning compounded semaglutide and tirzepatide products appears on your website:\n“clinically proven ingredients”\nCompounded drug products are not FDA-approved. Your claim implies that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","Aspen Aesthetics dba Fifty 410","aspen-aesthetics-dba-fifty-410-721481-02202026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspen-aesthetics-dba-fifty-410-721481-02202026","2026-10-26T08:07:58.453016+00:00","2026-03-03","721481","2026-08-19T04:52:57.164+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-02-20",{"id":74,"raw":75,"subject":60,"body_html":77,"body_text":78,"firm_name":79,"letter_id":80,"created_at":65,"fei_number":19,"letter_url":81,"updated_at":82,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":83,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":84,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},285,[56,57,76,11,59,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdeluxe-iv-aesthetics-pllc-dba-deluxe-iv-and-aesthetics-721447-02202026\">Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10977 Prairie Grove Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89179\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:admin@deluxeivaesthetics.com\"> admin@deluxeivaesthetics.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>Deluxe IV and Aesthetics:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fdeluxeivaesthetics.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide and tirzepatide products displayed on your website identify “Deluxe IV and Aesthetics” on the pictured label, suggesting Deluxe IV and Aesthetics is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that Deluxe IV and Aesthetics is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Same active pharmaceutical ingredient in Ozempic® and Mounjaro®.”\u003C\u002Fli>\u003Cli>“Semaglutide is the active pharmaceutical ingredient in Ozempic®*, Rybelsus®*, and Wegovy®*”\u003C\u002Fli>\u003Cli>“Tirzepatide is the active pharmaceutical ingredient in Mounjaro®* and Zepbound®*.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nDeluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics\n\n10977 Prairie Grove Rd.\n\nLas Vegas, NV 89179\n\nUnited States\n\nadmin@deluxeivaesthetics.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nDeluxe IV and Aesthetics:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fdeluxeivaesthetics.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide and tirzepatide products displayed on your website identify “Deluxe IV and Aesthetics” on the pictured label, suggesting Deluxe IV and Aesthetics is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that Deluxe IV and Aesthetics is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nAdditionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“Same active pharmaceutical ingredient in Ozempic® and Mounjaro®.”\n“Semaglutide is the active pharmaceutical ingredient in Ozempic®*, Rybelsus®*, and Wegovy®*”\n“Tirzepatide is the active pharmaceutical ingredient in Mounjaro®* and Zepbound®*.”\nCompounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics","deluxe-iv-aesthetics-pllc-dba-deluxe-iv-and-aesthetics-721447-02202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdeluxe-iv-aesthetics-pllc-dba-deluxe-iv-and-aesthetics-721447-02202026","2026-10-26T08:08:22.838477+00:00","721447","2026-08-19T04:53:39.82+00:00",{"id":86,"raw":87,"subject":91,"body_html":92,"body_text":93,"firm_name":94,"letter_id":95,"created_at":65,"fei_number":19,"letter_url":96,"updated_at":97,"action_type":22,"case_status":23,"posted_date":98,"marcs_cms_no":99,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":100,"body_fetched_at":101,"delivery_method":102,"recipient_title":19,"reference_number":19,"action_taken_date":103,"medical_device_id":19,"response_letter_date":19},236,[88,89,90,11,91,13,13,13],"\u003Ctime datetime=\"2026-04-09T04:00:00Z\">04\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-01T04:00:00Z\">04\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpure-indulgence-aesthetics-723267-04012026\">Pure Indulgence Aesthetics\u003C\u002Fa>","Drug Supply Chain Security Act (DSCSA) Violations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Bridget M. Goddard\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Pure Indulgence Aesthetics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1695 East Southlake Boulevard Suite 150\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Southlake\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76092\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@pureindulgenceaesthetics.com\"> info@pureindulgenceaesthetics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 723267\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>April 1, 2026\u003C\u002Fp>\u003Cp>FEI: 3041017461\u003C\u002Fp>\u003Cp>Ms. Goddard:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your facility, Pure Indulgence Aesthetics (Pure Indulgence), FEI 3041017461, 1695 East Southlake Boulevard Southlake, TX 76092, on December 2nd, 3rd, and 12th, 2025. You identified yourself as the manager and the most responsible person at the facility.\u003C\u002Fp>\u003Cp>The Drug Supply Chain Security Act (DSCSA) (Title II of Public Law 113-54), enacted by Congress on November 27, 2013, added section 582 to the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). Section 582 of the FD&amp;C Act (21 U.S.C. 360eee-1) specifies the requirements that certain entities in the pharmaceutical distribution supply chain (including dispensers, as defined by the DSCSA) must follow related to product tracing, product identification, verification, and authorized trading partners.\u003C\u002Fp>\u003Cp>Pure Indulgence operates as a medical spa under the supervision of a medical doctor. Certain employees working at Pure Indulgence are authorized to dispense and administer human prescription drugs under this medical doctor’s direction and supervision. The DSCSA includes in its definition of a dispenser any “person authorized to dispense or administer human prescription drugs.” Pure Indulgence therefore operates as a “dispenser” under section 581(3) of the DSCSA, and your firm is subject to certain provisions of section 582(d) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations by your firm of requirements in section 582(d) of the FD&amp;C Act. These requirements are intended to help preserve the security of the supply chain for certain prescription drug products, thereby protecting patients from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to Pure Indulgence at its Southlake, Texas facility on December 12, 2025. Observations highlighted FDA’s concerns about Pure Indulgence’s sourcing of botulinum neurotoxin type A products. FDA reviewed Pure Indulgence’s response submitted on December 17, 2025.\u003C\u002Fp>\u003Cp>Furthermore, FDA-approved botulinum toxin products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning indicates the product may cause symptoms of botulism, which attacks the body’s nerves and causes muscle weakness that can lead to difficulty breathing and even death.\u003C\u002Fp>\u003Cp>\u003Cstrong>DSCSA Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During FDA’s inspection, our investigators observed that your firm failed to comply with various requirements of the DSCSA. Specific violations include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm was unable to demonstrate compliance with the requirement to conduct transactions with only authorized trading partners (FD&amp;C Act Section 582(d)(3)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 582(d)(3) of the FD&amp;C Act, trading partners of a dispenser must be authorized trading partners. A trading partner is considered authorized if it meets the definitions established in section 581(2) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>During the inspection, FDA conducted a thorough analysis of your firm’s purchase records and patient dispensing records with respect to Botox® (onabotulinumtoxinA), a botulinum neurotoxin type A product. It was determined that your firm dispensed significantly more Botox units than documented purchases from AbbVie (the manufacturer of Botox), thereby indicating a major discrepancy.\u003C\u002Fp>\u003Cp>Purchase records provided by both your firm and AbbVie (an authorized trading partner in accordance with section 581(2)(A) show your firm received \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials (\u003Cstrong>(b)(4)\u003C\u002Fstrong> units) from AbbVie between December 18, 2024, and December 01, 2025. Patient treatment records, however, indicate that your firm administered product identified as “Botox” to \u003Cstrong>(b)(4)\u003C\u002Fstrong> patients between January 1, 2025, and December 1, 2025, with an estimated \u003Cstrong>(b)(4)\u003C\u002Fstrong> units dispensed. This represents a discrepancy of \u003Cstrong>(b)(4)\u003C\u002Fstrong> units (approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials) between the amount of Botox indicated in your purchase records and the amount of product administered to patients. During the inspection, you indicated that you would expect to dispense approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of Botox, or \u003Cstrong>(b)(4)\u003C\u002Fstrong> units \u003Cstrong>(b)(4)\u003C\u002Fstrong>. When asked by FDA how much Botox is typically ordered, you noted that you place about \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These descriptions of purchasing and dispensing align with what is indicated in the patient treatment records, but not with the records provided to FDA by both your firm and AbbVie documenting actual purchasing of Botox.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> During the inspection, you did not provide any explanation or justification for the discrepancy between the purchase records and treatment records.\u003C\u002Fp>\u003Cp>FDA also notes that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> purchase orders you made for Botox from AbbVie dating back to December 2024 were all for \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials. The only purchase record you were able to provide demonstrating a purchase of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials was for an order placed on December 2, 2025, after FDA investigators arrived and were actively conducting the inspection.\u003C\u002Fp>\u003Cp>Based on records summarized above and reviewed by FDA, your firm did not purchase enough Botox from AbbVie to supply patients with the quantity of authentic Botox indicated in patient records. This discrepancy shows that your firm obtained product from unauthorized sources (i.e., entities that are not authorized trading partners) and then claimed such product was authentic AbbVie Botox. Based on the thorough review of your purchasing records and patient treatment records, you have been unable to demonstrate compliance with the requirement under section 582(d)(3) to conduct transactions only with authorized trading partners.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to engage in transactions involving only product with a product identifier (FD&amp;C Act Section 582(d)(2))\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 582(d)(2) of the FD&amp;C Act, a dispenser may only engage in transactions\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> involving a product\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> if that product is encoded with a product identifier. A product identifier, as defined in section 581(14) of the FD&amp;C Act, is a standardized graphic that includes, in both human and machine-readable format, the product’s standardized numerical identifier,\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> the lot number, and the expiration date of the product. Under section 582(b)(2) and (e)(2) of the FD&amp;C Act, manufacturers and repackagers are required to affix or imprint product identifiers to packages and homogenous cases of product.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>During the inspection, FDA identified an unlabeled, clear vial containing a ring of white powder disposed of in your facility's trash. While you denied any knowledge or recognition of this product, you identified yourself as the most responsible person during the inspection. FDA later confirmed by laboratory analysis that this vial contained botulinum neurotoxin type A, the same active ingredient as Botox. The shape of the unlabeled vial found at your facility was not the same as an authentic vial of Botox manufactured by AbbVie.\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA investigators asked if you were able to provide a label or packaging for this product with required information, including a product identifier. In response, you denied any knowledge of the product and claimed not to recognize it. Therefore, you provided no evidence that the unlabeled, clear vial had been in a package or homogenous case that properly contained a required product identifier.\u003C\u002Fp>\u003Cp>An onabotulinumtoxinA product, such as Botox, is a prescription drug and is a “product” as defined by 581(13) of the FD&amp;C Act. The product found at your facility lacked proper labeling and you were unable to provide a label or packaging that contained a product identifier, as required under section 582(d)(2).\u003C\u002Fp>\u003Cp>\u003Cstrong>Your Response to the FDA Form 483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has reviewed your December 17, 2025, response to our Form FDA 483 in detail. FDA acknowledges the corrective actions Pure Indulgence describes in its response, but FDA finds Pure Indulgence’s response to be inadequate. Pure Indulgence’s response does not provide information about how you will ensure compliance with the DSCSA requirements in the FD&amp;C Act moving forward, and your response lacks any supporting documentation such as new policies and procedures to ensure compliance or a description of how trading partner status will be verified. In addition, Pure Indulgence’s response does not address the large discrepancy between the amount of Botox purchased from AbbVie and the amount of product administered to patients.\u003C\u002Fp>\u003Cp>Other reasons Pure Indulgence’s response is insufficient include, but are not limited to, the following:\u003C\u002Fp>\u003Cul>\u003Cli>Your response notes that you performed a retrospective review of purchasing records, administration documentation, and patient charts related to botulinum toxin administration and determined that no adverse events were identified. It is impossible for FDA to verify this statement since you did not provide any documentation or identify the products you dispensed and administered to patients at your facility, making a true evaluation of adverse events or potentially applicable recalls impossible. In addition, FDA cannot evaluate your review because you have not provided any documentation or explanation about how you conducted your adverse event evaluation. This is particularly concerning from a public health perspective given that FDA-approved botulinum neurotoxin type A products contain a boxed warning. The ability to conduct a speedy and effective recall of drug products when necessary is critical to public health. When a facility obtains drug products from unauthorized sources and does not have safeguards in place to identify adverse events, effective recalls are not possible.\u003C\u002Fli>\u003Cli>Your response notes that you have appointed a designated “drug custodian” with sole responsibility and authority for ordering and receiving prescription drugs; however, you provide no documentation demonstrating who that individual is or providing their qualifications. Based on the response, there is no reason to believe that you, Bridget Goddard, are not the drug custodian. This is especially concerning given the observations in the warning letter. Further we note that you have a history of obtaining unapproved products from foreign, unverified sources.\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fli>\u003Cli>At the inspection, FDA investigators were told of your firm’s practice of drawing product identified as Botox into 10-unit syringes and holding a supply of pre-filled syringes at the facility to be administered to patients. Your response states that “the Facility prohibits storage or use of prescription drug products outside original manufacturer packaging.” However, without further detailed protocols in place, we are concerned that you will continue to remove the product from manufacturer vials prior to administration to patients.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Pure Indulgence’s response to FDA Form 483 does not indicate that sufficient remediation efforts have been taken. FDA is sending this advisory letter to Pure Indulgence because of the inherent risk to patients introduced through your firm’s aforementioned actions.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address the violations described herein may result in regulatory or legal action without further notice, including seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of your receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct the violations identified in this warning letter. Please include an explanation of each step being taken to prevent the recurrence of violations and include copies of related documentation. If you disagree with the characterization of the violations of the FD&amp;C Act in this warning letter, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the corrections.\u003C\u002Fp>\u003Cp>Please send your electronic reply, or any questions regarding the contents of this letter, to: DSCSAInspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Please identify your responses with the unique identifier: CMS 723267.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Sangeeta Vaswani Chatterjee, Pharm.D.\u003Cbr>Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> There was no discrepancy between the purchase records provided by both Pure Indulgence and AbbVie to FDA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As defined in section 581(24) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As defined in section 581(13) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> As defined in section 581(20) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> “Package” and “homogenous case” as defined in sections 581(11) and 581(7), respectively, of the FD&amp;C Act. As specified in section 581(11), “package” means the smallest individual saleable unit of product for distribution by a manufacturer or repackager that is intended by the manufacturer for ultimate sale to the dispenser, and “individual saleable unit” means the smallest container of product introduced into commerce by the manufacturer or repackager that is intended by the manufacturer or repackager for individual sale to a dispenser.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> This product is not a compounded drug, which is not a “product” for purposes of the DSCSA per section 581(13), because it does not meet relevant requirements for drug compounding under sections 503A and 503B of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.justice.gov\u002Fusao-cdca\u002Fpr\u002Fnurse-who-operated-spa-laguna-niguel-agrees-plead-guilty-illegally-dispensing-botox-not\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nBridget M. Goddard\n\nRecipient Title\n\nManager\n\nPure Indulgence Aesthetics\n\n1695 East Southlake Boulevard Suite 150\n\nSouthlake, TX 76092\n\nUnited States\n\ninfo@pureindulgenceaesthetics.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 723267\nApril 1, 2026\nFEI: 3041017461\nMs. Goddard:\nThe U.S. Food and Drug Administration (FDA) inspected your facility, Pure Indulgence Aesthetics (Pure Indulgence), FEI 3041017461, 1695 East Southlake Boulevard Southlake, TX 76092, on December 2nd, 3rd, and 12th, 2025. You identified yourself as the manager and the most responsible person at the facility.\nThe Drug Supply Chain Security Act (DSCSA) (Title II of Public Law 113-54), enacted by Congress on November 27, 2013, added section 582 to the Federal Food, Drug, and Cosmetic Act (FD&C Act). Section 582 of the FD&C Act (21 U.S.C. 360eee-1) specifies the requirements that certain entities in the pharmaceutical distribution supply chain (including dispensers, as defined by the DSCSA) must follow related to product tracing, product identification, verification, and authorized trading partners.\nPure Indulgence operates as a medical spa under the supervision of a medical doctor. Certain employees working at Pure Indulgence are authorized to dispense and administer human prescription drugs under this medical doctor’s direction and supervision. The DSCSA includes in its definition of a dispenser any “person authorized to dispense or administer human prescription drugs.” Pure Indulgence therefore operates as a “dispenser” under section 581(3) of the DSCSA, and your firm is subject to certain provisions of section 582(d) of the FD&C Act.\nThis warning letter summarizes significant violations by your firm of requirements in section 582(d) of the FD&C Act. These requirements are intended to help preserve the security of the supply chain for certain prescription drug products, thereby protecting patients from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.\nFDA issued a Form FDA 483 to Pure Indulgence at its Southlake, Texas facility on December 12, 2025. Observations highlighted FDA’s concerns about Pure Indulgence’s sourcing of botulinum neurotoxin type A products. FDA reviewed Pure Indulgence’s response submitted on December 17, 2025.\nFurthermore, FDA-approved botulinum toxin products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning indicates the product may cause symptoms of botulism, which attacks the body’s nerves and causes muscle weakness that can lead to difficulty breathing and even death.\nDSCSA Violations\nDuring FDA’s inspection, our investigators observed that your firm failed to comply with various requirements of the DSCSA. Specific violations include, but may not be limited to, the following:\n1. Your firm was unable to demonstrate compliance with the requirement to conduct transactions with only authorized trading partners (FD&C Act Section 582(d)(3)).\nUnder section 582(d)(3) of the FD&C Act, trading partners of a dispenser must be authorized trading partners. A trading partner is considered authorized if it meets the definitions established in section 581(2) of the FD&C Act.\nDuring the inspection, FDA conducted a thorough analysis of your firm’s purchase records and patient dispensing records with respect to Botox® (onabotulinumtoxinA), a botulinum neurotoxin type A product. It was determined that your firm dispensed significantly more Botox units than documented purchases from AbbVie (the manufacturer of Botox), thereby indicating a major discrepancy.\nPurchase records provided by both your firm and AbbVie (an authorized trading partner in accordance with section 581(2)(A) show your firm received (b)(4) vials ((b)(4) units) from AbbVie between December 18, 2024, and December 01, 2025. Patient treatment records, however, indicate that your firm administered product identified as “Botox” to (b)(4) patients between January 1, 2025, and December 1, 2025, with an estimated (b)(4) units dispensed. This represents a discrepancy of (b)(4) units (approximately (b)(4) vials) between the amount of Botox indicated in your purchase records and the amount of product administered to patients. During the inspection, you indicated that you would expect to dispense approximately (b)(4) vials of Botox, or (b)(4) units (b)(4). When asked by FDA how much Botox is typically ordered, you noted that you place about (b)(4). These descriptions of purchasing and dispensing align with what is indicated in the patient treatment records, but not with the records provided to FDA by both your firm and AbbVie documenting actual purchasing of Botox.1 During the inspection, you did not provide any explanation or justification for the discrepancy between the purchase records and treatment records.\nFDA also notes that the (b)(4) purchase orders you made for Botox from AbbVie dating back to December 2024 were all for (b)(4) vials. The only purchase record you were able to provide demonstrating a purchase of (b)(4) vials was for an order placed on December 2, 2025, after FDA investigators arrived and were actively conducting the inspection.\nBased on records summarized above and reviewed by FDA, your firm did not purchase enough Botox from AbbVie to supply patients with the quantity of authentic Botox indicated in patient records. This discrepancy shows that your firm obtained product from unauthorized sources (i.e., entities that are not authorized trading partners) and then claimed such product was authentic AbbVie Botox. Based on the thorough review of your purchasing records and patient treatment records, you have been unable to demonstrate compliance with the requirement under section 582(d)(3) to conduct transactions only with authorized trading partners.\n2. Your firm failed to engage in transactions involving only product with a product identifier (FD&C Act Section 582(d)(2))\nUnder section 582(d)(2) of the FD&C Act, a dispenser may only engage in transactions2 involving a product3 if that product is encoded with a product identifier. A product identifier, as defined in section 581(14) of the FD&C Act, is a standardized graphic that includes, in both human and machine-readable format, the product’s standardized numerical identifier,4 the lot number, and the expiration date of the product. Under section 582(b)(2) and (e)(2) of the FD&C Act, manufacturers and repackagers are required to affix or imprint product identifiers to packages and homogenous cases of product.5\nDuring the inspection, FDA identified an unlabeled, clear vial containing a ring of white powder disposed of in your facility's trash. While you denied any knowledge or recognition of this product, you identified yourself as the most responsible person during the inspection. FDA later confirmed by laboratory analysis that this vial contained botulinum neurotoxin type A, the same active ingredient as Botox. The shape of the unlabeled vial found at your facility was not the same as an authentic vial of Botox manufactured by AbbVie.6\nFDA investigators asked if you were able to provide a label or packaging for this product with required information, including a product identifier. In response, you denied any knowledge of the product and claimed not to recognize it. Therefore, you provided no evidence that the unlabeled, clear vial had been in a package or homogenous case that properly contained a required product identifier.\nAn onabotulinumtoxinA product, such as Botox, is a prescription drug and is a “product” as defined by 581(13) of the FD&C Act. The product found at your facility lacked proper labeling and you were unable to provide a label or packaging that contained a product identifier, as required under section 582(d)(2).\nYour Response to the FDA Form 483\nFDA has reviewed your December 17, 2025, response to our Form FDA 483 in detail. FDA acknowledges the corrective actions Pure Indulgence describes in its response, but FDA finds Pure Indulgence’s response to be inadequate. Pure Indulgence’s response does not provide information about how you will ensure compliance with the DSCSA requirements in the FD&C Act moving forward, and your response lacks any supporting documentation such as new policies and procedures to ensure compliance or a description of how trading partner status will be verified. In addition, Pure Indulgence’s response does not address the large discrepancy between the amount of Botox purchased from AbbVie and the amount of product administered to patients.\nOther reasons Pure Indulgence’s response is insufficient include, but are not limited to, the following:\nYour response notes that you performed a retrospective review of purchasing records, administration documentation, and patient charts related to botulinum toxin administration and determined that no adverse events were identified. It is impossible for FDA to verify this statement since you did not provide any documentation or identify the products you dispensed and administered to patients at your facility, making a true evaluation of adverse events or potentially applicable recalls impossible. In addition, FDA cannot evaluate your review because you have not provided any documentation or explanation about how you conducted your adverse event evaluation. This is particularly concerning from a public health perspective given that FDA-approved botulinum neurotoxin type A products contain a boxed warning. The ability to conduct a speedy and effective recall of drug products when necessary is critical to public health. When a facility obtains drug products from unauthorized sources and does not have safeguards in place to identify adverse events, effective recalls are not possible.\nYour response notes that you have appointed a designated “drug custodian” with sole responsibility and authority for ordering and receiving prescription drugs; however, you provide no documentation demonstrating who that individual is or providing their qualifications. Based on the response, there is no reason to believe that you, Bridget Goddard, are not the drug custodian. This is especially concerning given the observations in the warning letter. Further we note that you have a history of obtaining unapproved products from foreign, unverified sources.7\nAt the inspection, FDA investigators were told of your firm’s practice of drawing product identified as Botox into 10-unit syringes and holding a supply of pre-filled syringes at the facility to be administered to patients. Your response states that “the Facility prohibits storage or use of prescription drug products outside original manufacturer packaging.” However, without further detailed protocols in place, we are concerned that you will continue to remove the product from manufacturer vials prior to administration to patients.\nConclusion\nPure Indulgence’s response to FDA Form 483 does not indicate that sufficient remediation efforts have been taken. FDA is sending this advisory letter to Pure Indulgence because of the inherent risk to patients introduced through your firm’s aforementioned actions.\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address the violations described herein may result in regulatory or legal action without further notice, including seizure and injunction.\nWithin fifteen (15) working days of your receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct the violations identified in this warning letter. Please include an explanation of each step being taken to prevent the recurrence of violations and include copies of related documentation. If you disagree with the characterization of the violations of the FD&C Act in this warning letter, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the corrections.\nPlease send your electronic reply, or any questions regarding the contents of this letter, to: DSCSAInspections@fda.hhs.gov.\nPlease identify your responses with the unique identifier: CMS 723267.\nSincerely,\n\u002FS\u002F\nSangeeta Vaswani Chatterjee, Pharm.D.\nDirector\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 There was no discrepancy between the purchase records provided by both Pure Indulgence and AbbVie to FDA.\n2 As defined in section 581(24) of the FD&C Act.\n3 As defined in section 581(13) of the FD&C Act.\n4 As defined in section 581(20) of the FD&C Act.\n5 “Package” and “homogenous case” as defined in sections 581(11) and 581(7), respectively, of the FD&C Act. As specified in section 581(11), “package” means the smallest individual saleable unit of product for distribution by a manufacturer or repackager that is intended by the manufacturer for ultimate sale to the dispenser, and “individual saleable unit” means the smallest container of product introduced into commerce by the manufacturer or repackager that is intended by the manufacturer or repackager for individual sale to a dispenser.\n6 This product is not a compounded drug, which is not a “product” for purposes of the DSCSA per section 581(13), because it does not meet relevant requirements for drug compounding under sections 503A and 503B of the FD&C Act.\n7 https:\u002F\u002Fwww.justice.gov\u002Fusao-cdca\u002Fpr\u002Fnurse-who-operated-spa-laguna-niguel-agrees-plead-guilty-illegally-dispensing-botox-not","Pure Indulgence Aesthetics","pure-indulgence-aesthetics-723267-04012026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpure-indulgence-aesthetics-723267-04012026","2026-10-26T08:09:45.60058+00:00","2026-04-09","723267","Bridget M. Goddard","2026-08-19T04:48:34.792+00:00","VIA UPS","2026-04-01",5,{"510k":106,"classification":107,"enforcement":108,"event":109,"event_backfill":110,"pma":111,"warning_letter":112},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]